Zantac Litigation is Born “The best starting point involves a private company known as Valisure. Valisure theorized that ranitidine [aka Zantac] has the potential to degrade into a carcinogen known as ...
The common claim in the lawsuits is that a contaminant in Zantac (ranitidine) called N-nitrosodimethylamine (NDMA) – as well as other ranitidine products – increased the risk of cancer.
The company has agreed to pay $2.2 billion to settle around 80,000 state court product liability cases alleging injury from Zantac (ranitidine), most of which had been consolidated in a Delaware ...
Plaintiffs argued that the company knew that Zantac’s active ingredient, ranitidine, turned into the potential carcinogen NDMA under certain conditions. The US Food and Drug Administration asked ...
Class action and personal injury lawsuits have been filed in US courts after the Food and Drug Administration warned in 2019 that some ranitidine drugs including Zantac contained low levels of an ...
Reuters on MSN1mon
GSK agrees to settle about 80,000 Zantac lawsuits for up to $2.2 billionThe agency cited concerns that ranitidine could degrade into NDMA, a carcinogen, over time or when exposed to heat. Pfizer ...
The agency cited concerns that ranitidine could degrade into NDMA, a carcinogen, over time or when exposed to heat. Pfizer has agreed to settle most of the Zantac cases against it in state court ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback